Allogene Therapeutics Inc
NASDAQ:ALLO

Watchlist Manager
Allogene Therapeutics Inc Logo
Allogene Therapeutics Inc
NASDAQ:ALLO
Watchlist
Price: 2.635 USD -3.13%
Market Cap: 551m USD
Have any thoughts about
Allogene Therapeutics Inc?
Write Note

Intrinsic Value

ALLO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ALLO stock under the Base Case scenario is 3.087 USD. Compared to the current market price of 2.635 USD, Allogene Therapeutics Inc is Undervalued by 15%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ALLO Intrinsic Value
3.087 USD
Undervaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Allogene Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ALLO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ALLO?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Allogene Therapeutics Inc

Provide an overview of the primary business activities
of Allogene Therapeutics Inc.

What unique competitive advantages
does Allogene Therapeutics Inc hold over its rivals?

What risks and challenges
does Allogene Therapeutics Inc face in the near future?

Summarize the latest earnings call
of Allogene Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Allogene Therapeutics Inc.

Provide P/S
for Allogene Therapeutics Inc.

Provide P/E
for Allogene Therapeutics Inc.

Provide P/OCF
for Allogene Therapeutics Inc.

Provide P/FCFE
for Allogene Therapeutics Inc.

Provide P/B
for Allogene Therapeutics Inc.

Provide EV/S
for Allogene Therapeutics Inc.

Provide EV/GP
for Allogene Therapeutics Inc.

Provide EV/EBITDA
for Allogene Therapeutics Inc.

Provide EV/EBIT
for Allogene Therapeutics Inc.

Provide EV/OCF
for Allogene Therapeutics Inc.

Provide EV/FCFF
for Allogene Therapeutics Inc.

Provide EV/IC
for Allogene Therapeutics Inc.

Show me price targets
for Allogene Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Allogene Therapeutics Inc?

How accurate were the past Revenue estimates
for Allogene Therapeutics Inc?

What are the Net Income projections
for Allogene Therapeutics Inc?

How accurate were the past Net Income estimates
for Allogene Therapeutics Inc?

What are the EPS projections
for Allogene Therapeutics Inc?

How accurate were the past EPS estimates
for Allogene Therapeutics Inc?

What are the EBIT projections
for Allogene Therapeutics Inc?

How accurate were the past EBIT estimates
for Allogene Therapeutics Inc?

Compare the revenue forecasts
for Allogene Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Allogene Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Allogene Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Allogene Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Allogene Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Allogene Therapeutics Inc with its peers.

Analyze the financial leverage
of Allogene Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Allogene Therapeutics Inc.

Provide ROE
for Allogene Therapeutics Inc.

Provide ROA
for Allogene Therapeutics Inc.

Provide ROIC
for Allogene Therapeutics Inc.

Provide ROCE
for Allogene Therapeutics Inc.

Provide Gross Margin
for Allogene Therapeutics Inc.

Provide Operating Margin
for Allogene Therapeutics Inc.

Provide Net Margin
for Allogene Therapeutics Inc.

Provide FCF Margin
for Allogene Therapeutics Inc.

Show all solvency ratios
for Allogene Therapeutics Inc.

Provide D/E Ratio
for Allogene Therapeutics Inc.

Provide D/A Ratio
for Allogene Therapeutics Inc.

Provide Interest Coverage Ratio
for Allogene Therapeutics Inc.

Provide Altman Z-Score Ratio
for Allogene Therapeutics Inc.

Provide Quick Ratio
for Allogene Therapeutics Inc.

Provide Current Ratio
for Allogene Therapeutics Inc.

Provide Cash Ratio
for Allogene Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Allogene Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Allogene Therapeutics Inc?

What is the current Free Cash Flow
of Allogene Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Allogene Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Allogene Therapeutics Inc

Current Assets 304.4m
Cash & Short-Term Investments 291.6m
Other Current Assets 12.9m
Non-Current Assets 284.7m
Long-Term Investments 111.8m
PP&E 135.3m
Other Non-Current Assets 37.6m
Current Liabilities 32.6m
Accounts Payable 5.5m
Accrued Liabilities 27.1m
Non-Current Liabilities 92.8m
Other Non-Current Liabilities 92.8m
Efficiency

Earnings Waterfall
Allogene Therapeutics Inc

Revenue
117k USD
Operating Expenses
-511.6m USD
Operating Income
-511.5m USD
Other Expenses
-13.4m USD
Net Income
-524.9m USD

Free Cash Flow Analysis
Allogene Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ALLO Profitability Score
Profitability Due Diligence

Allogene Therapeutics Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
12/100
Profitability
Score

Allogene Therapeutics Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.

ALLO Solvency Score
Solvency Due Diligence

Allogene Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Allogene Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALLO Price Targets Summary
Allogene Therapeutics Inc

Wall Street analysts forecast ALLO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALLO is 9.784 USD with a low forecast of 4.545 USD and a high forecast of 14.7 USD.

Lowest
Price Target
4.545 USD
72% Upside
Average
Price Target
9.784 USD
271% Upside
Highest
Price Target
14.7 USD
458% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ALLO?

Click here to dive deeper.

Dividends

Allogene Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ALLO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Allogene Therapeutics Inc Logo
Allogene Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

569.8m USD

Dividend Yield

0%

Description

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 310 full-time employees. The company went IPO on 2018-10-11. The firm is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-715 plus nirogacestat, ALLO-605, ALLO-316, and ALLO-647.

Contact

CALIFORNIA
South San Francisco
210 E Grand Ave
+16504572700.0
www.allogene.com

IPO

2018-10-11

Employees

310

Officers

Co-Founder & Executive Chairman
Dr. Arie S. Belldegrun F.A.C.S., M.D.
Co-Founder, President, CEO & Director
Dr. David D. Chang M.D., Ph.D.
Co-Founder & Director
Mr. Joshua A. Kazam
Executive VP & Chief Technical Officer
Mr. Timothy L. Moore Ph.D.
Executive VP of Research & Development and Chief Medical Officer
Dr. Zachary J. Roberts M.D., Ph.D.
Executive VP & CFO
Mr. Geoffrey M. Parker
Show More
Senior VP, Corporate Controller & Principal Accounting Officer
Ms. Annie Yoshiyama
Senior VP, General Counsel, Compliance Officer & Corporate Secretary
Mr. Earl M. Douglas Esq.
Chief People Officer
Ms. Susan R. Lundeen
Executive VP, Chief Corporate Affairs & Brand Strategy Officer
Ms. Christine Cassiano
Show Less

See Also

Discover More
What is the Intrinsic Value of one ALLO stock?

The intrinsic value of one ALLO stock under the Base Case scenario is 3.087 USD.

Is ALLO stock undervalued or overvalued?

Compared to the current market price of 2.635 USD, Allogene Therapeutics Inc is Undervalued by 15%.

Back to Top